Final report of University Hospital Hradec Kralove to the clinical trial protocol no. B1481022

Abstract

Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.

Keywords

• Pf-04950615
• Cardiovascular Events